tirzepatide clinical trial New trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss Eli Lilly plans diabetes drug

Rogan, who began TRT in his 40s and has discussed using doses sufficient to maintain levels he describes as "high-normal," falls into a demographic space adjacent to, but not perfectly overlapping with, the TRAVERSE population

Conflicts of Interest SFD, JL, and DD have no conflicts of interest to declare

Studies were selected based on their relevance to the interactions between GLP-1 receptor agonists and the gut microbiota, with particular attention to mechanisms potentially influencing treatment response and metabolic outcomes

Second, the high bioavailability of orforglipron translates to lower inter-individual pharmacokinetic variability compared to oral semaglutide